We came across a bullish thesis on Pfizer Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.'s share was trading at $25.86 as of January 28th. PFE’s trailing and forward P/E were 15.41 and 9.14, respectively according to Yahoo Finance. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. PFE has strengthened its oncology leadership ...

格隆汇2月5日｜美股三大指数收盘涨跌不一，道指涨0.53%，纳指跌1.51%，标普500指数跌0.51%，热 门科技股普遍下跌，AMD跌超17%，创2017年以来最差单日表现，英伟达、特斯拉、博通、Meta跌超 3%，谷歌、亚马逊跌超2%，苹果涨超2%。半导体设备与材料、存储概念股、加密矿企跌幅居前，闪迪 跌近16%，美光科技跌超9%，西部数据跌超7%，应用材料、Coinbase跌超6%，阿斯麦跌超3%。减肥药 概念股、住宅地产涨幅居前，礼来涨超10%，安进涨超8%，辉瑞涨近4%。 ...

每经AI快讯，美股三大指数收盘涨跌不一，道指涨0.53%，纳指跌1.51%，标普500指数跌0.51%，热门 科技股普遍下跌，AMD跌超17%，英伟达、特斯拉、博通、Meta跌超3%，谷歌、亚马逊跌超2%，苹果 涨超2%。半导体设备与材料、存储概念股、加密矿企跌幅居前，闪迪跌近16%，美光科技跌超9%，西 部数据跌超7%，应用材料、Coinbase跌超6%，阿斯麦跌超3%。减肥药概念股、住宅地产涨幅居前，礼 来涨超10%，安进涨超8%，辉瑞涨近4%。 ...

Pfizer Inc. (NYSE:PFE) is one of the best large cap stocks to buy under $50. On February 3, Pfizer announced positive topline results from its Phase 2b VESPER-3 study of PF-08653944 (MET-097i), which is an injectable GLP-1 receptor agonist. The trial met its primary endpoint and showed a statistically significant, placebo-adjusted weight loss of up to 12.3% at 28 weeks. Notably, patients continued to lose weight after transitioning from weekly to monthly dosing, with no plateau observed by the end of the 2 ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Market Overview - Concerns exist regarding a potential market crash in 2026, with historical data suggesting a bear market may be imminent due to high valuations, particularly in the AI sector [1][5]. Company Analysis: Pfizer - Pfizer's market cap stands at $152 billion, with shares currently priced at $25.77, reflecting a decline of 3.34% [8]. - The company is facing challenges as it will lose patent exclusivity for key products like Eliquis and Xtandi in the coming years, which may impact its financial performance [7]. - Despite recent struggles, Pfizer has a robust pipeline in therapeutic areas such as oncology and weight management, and is leveraging AI to enhance operational efficiency [9]. - The company's earnings remain resilient, and it is trading at 9 times forward earnings, significantly lower than the healthcare sector average of 18.6, indicating potential undervaluation [9]. - In the event of an AI-driven market crash, Pfizer's stock is expected to decline less than major AI companies, positioning it favorably for long-term recovery [10].

Core Insights - Pfizer is currently facing challenges in generating growth, with its stock declining since 2021 when it last saw a significant gain of over 60% due to strong demand for COVID products [1][2] - Despite current struggles, Pfizer's management is optimistic about future growth, citing multiple potential catalysts and plans to launch over 20 pivotal late-stage trials in 2026 [3][4] Company Performance - Pfizer's stock has been trading at a deep discount, currently priced at $25.77, down 3.32% on the day, with a market cap of $152 billion [5][6] - The stock is trading at an estimated 9 times its forward earnings, significantly lower than the average S&P 500 stock, which trades at 22 times its estimated future profits [6] Investment Appeal - Pfizer offers a high dividend yield of 6.45%, making it an attractive option for investors seeking safe dividend stocks [6][7] - The potential for positive news from ongoing trials could lead to a rally in Pfizer's stock, which has been undervalued for an extended period [4][8]

Market Overview - The three major U.S. stock indices closed lower, with the Dow Jones down 0.34%, the Nasdaq down 1.43%, and the S&P 500 down 0.83% [1] - Popular technology stocks experienced declines, with Broadcom falling over 3%, and Microsoft, Nvidia, and Meta each dropping over 2% [1] Sector Performance - The rare earth, non-ferrous metals, and precious metals sectors saw significant gains, with gold resources rising over 20%, Southern Copper up over 11%, Americas Silver up over 8%, and Pan American Silver up over 5% [1] - Conversely, application software, cryptocurrency, and weight loss drug stocks faced notable declines, with Novo Nordisk down over 14%, Coinbase and Circle each down over 4%, and Eli Lilly and Pfizer each down over 3% [1] Notable Company Movements - Walmart's stock increased by 2.94%, marking its market capitalization surpassing the $1 trillion milestone for the first time [1] - The Nasdaq Golden Dragon China Index fell by 0.94%, with significant declines in popular Chinese stocks such as Daqo New Energy down 5.6%, Bilibili down 4%, and Kingsoft Cloud down 3.5% [1] - Alibaba dropped 2.9%, while NIO rose 0.8%, Pony.ai increased by 2%, Huazhu up 2.2%, New Oriental up 2.3%, Li Auto up 2.7%, Canadian Solar up 4.1%, and Xpeng up 4.3% [1]

智通财经APP获悉，2月3日，辉瑞(PFE.US)宣布，其超长效注射用GLP-1受体激动剂(RA)PF'3944(MET- 097i)在2b期VESPER-3研究中取得积极顶线结果。该研究针对肥胖或超重、不合并2型糖尿病的成人患 者，评估每月一次维持给药方案。 PF'3944是一款超长效、完全偏向性的GLP-1受体激动剂，是辉瑞通过近期收购Metsera所获得的管线， 具有每月注射1次的给药潜力。目前正被开发为每周(QW)单药治疗及每月治疗方案，并探索与多种肽类 药物联合应用，包括胰淀素类似物PF-08653945(PF'3945；MET-233i)以及葡萄糖依赖性促胰岛素多肽受 体(GIPR)激动剂PF-08654696(MET-034i)。 结果显示，治疗第28周，第1组和第3组患者的体重分别较安慰剂组降低了10%和12.3%。这些数据表 明，在改为每月1次用药后，患者的体重下降稳健且持续，第28周时仍未见平台期，预计到第64周之前 体重仍会持续下降。 在第28周期间，PF'3944也保持了良好且有利的安全性特征，与GLP-1RA类药物的特征一致。观察到的 胃肠道治疗期间不良事件(TEAEs)以轻度或中度 ...

Core Insights - Pfizer Inc. reported a decline in fourth-quarter revenue primarily due to reduced demand for COVID-19 products, although earnings exceeded analyst forecasts due to strong performance in vaccines and oncology [1][3] Revenue Performance - Operational revenue for the quarter ended December 31 decreased by 3% to $17.6 billion, surpassing Bloomberg consensus estimates of $16.94 billion [3] - Revenue from Pfizer's COVID-19 vaccine fell by 35% year over year, while sales of its antiviral COVID treatment dropped by 70%, attributed to lower infection rates and reduced utilization in the U.S. [1] Product Performance - Strong growth was observed in Abrysvo, Pfizer's respiratory syncytial virus vaccine for adults aged 18 to 59 at risk, with global sales increasing by 136% due to international demand and pricing [2] - Oncology biosimilars also showed significant growth, with sales rising by 76% year over year [2] Earnings and Guidance - Adjusted earnings per share for the quarter were reported at $0.66, exceeding expectations of $0.57 [3] - Pfizer reaffirmed its full-year guidance, projecting revenue between $59.5 billion and $62.5 billion and adjusted diluted EPS of $2.80 to $3.00 [3] Clinical Developments - Pfizer's experimental obesity treatment showed promising results, demonstrating up to 12.3% weight loss in non-diabetic patients during a mid-stage clinical trial [4]